BIOVF:OTC-Swedish Orphan Biovitrum AB (publ) (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 22.50

Change

0.00 (0.00)%

Market Cap

USD 6.45B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


BIOVF Stock Forecast & Price:
Based on the Swedish Orphan Biovitrum AB (publ) stock forecasts from 0 analysts, the average analyst target price for Swedish Orphan Biovitrum AB (publ) is not available over the next 12 months. Swedish Orphan Biovitrum AB (publ)’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Swedish Orphan Biovitrum AB (publ) is Neutral, which is based on 7 positive signals and 6 negative signals. At the last closing, Swedish Orphan Biovitrum AB (publ)’s stock price was USD 22.50. Swedish Orphan Biovitrum AB (publ)’s stock price has changed by +6.13% over the past week, +2.63% over the past month and +16.70% over the last year.

No recent analyst target price found for Swedish Orphan Biovitrum AB (publ)
No recent average analyst rating found for Swedish Orphan Biovitrum AB (publ)

About Swedish Orphan Biovitrum AB (publ) (BIOVF:OTC)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY Merck KGaA ADR

+1.15 (+3.07%)

USD82.30B 24.18 14.39
MKGAF MERCK Kommanditgesellschaft au..

+1.46 (+0.77%)

USD82.30B 24.46 14.39
TKPHF Takeda Pharmaceutical Co. Ltd.

+0.79 (+2.84%)

USD43.27B 29.96 0.08
HLUYY H Lundbeck A/S ADR

N/A

USD21.85B 28.95 3.17
SGIOF Shionogi & Co. Ltd

+1.10 (+2.17%)

USD15.79B 18.06 0.08
SFOSF Shanghai Fosun Pharmaceutical ..

-0.09 (-2.49%)

USD15.69B 13.96 2.56
SGIOY Shionogi & Co Ltd ADR

+0.33 (+2.61%)

USD15.58B 17.84 0.08
TEVJF Teva Pharmaceutical Industries..

-0.95 (-7.95%)

USD13.27B 22.30 156.14
ESALF Eisai Co. Ltd

N/A

USD13.22B 36.88 0.12
ESALY Eisai Co Ltd ADR

+1.10 (+2.44%)

USD12.93B 36.36 0.12

ETFs Containing BIOVF

Symbol Name Weight Mer Price(Change) Market Cap
EXSE:F iShares STOXX Europe Smal.. 0.00 % 0.20 %

+0.19 (+0.61%)

USD0.40B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.35% 84% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.35% 80% B- 79% C+
Trailing 12 Months  
Capital Gain 16.70% 94% A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.70% 91% A- 82% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.60% 50% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.60% 47% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 25.37% 94% A 75% C
Risk Adjusted Return 25.99% 65% D 52% F
Market Capitalization 6.45B 95% A 85% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.24 25% F 24% F
Price/Book Ratio 2.60 34% F 34% F
Price / Cash Flow Ratio 1.18 21% F 38% F
EV/EBITDA 1.29 21% F 37% F
Management Effectiveness  
Return on Equity 11.06% 83% B 66% D
Return on Invested Capital 9.31% 69% D+ 66% D
Return on Assets 5.51% 88% B+ 82% B-
Debt to Equity Ratio 37.83% 23% F 41% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.40 72% C- 70% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.